Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
DBVT DBV Technologies	$10.80 -0.3%	$9.60	$2.20 ▼ $12.78	$296.74M	-0.59	191,165 shs	3,496 shs
MESO Mesoblast	$11.11 +0.8%	$11.20	$5.78 ▼ $22.00	$1.41B	2.39	277,575 shs	242,362 shs
SRRK Scholar Rock	$37.44 -1.8%	$32.78	$6.76 ▼ $46.98	$3.62B	0.33	1.30 million shs	687,816 shs
VCEL Vericel	$39.93 -3.2%	$41.87	$37.39 ▼ $63.00	$2.08B	1.32	421,282 shs	309,779 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	-92.21%
DBVT DBV Technologies	-0.46%	-6.40%	+23.85%	+47.54%	+170.34%
MESO Mesoblast	+0.82%	+2.97%	-6.40%	+9.57%	+49.53%
SRRK Scholar Rock	-1.78%	+5.91%	+13.42%	+33.71%	+352.72%
VCEL Vericel	-3.15%	-4.44%	-9.62%	-3.20%	-12.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.2622 of 5 stars	3.8	0.0	0.0	0.6	0.0	0.0
DBVT DBV Technologies	4.0026 of 5 stars	4.4	5.0	0.0	1.9	2.5	0.6
MESO Mesoblast	2.4659 of 5 stars	3.5	3.0	0.0	2.0	0.8	0.6
SRRK Scholar Rock	3.7732 of 5 stars	2.6	1.0	4.4	2.4	3.3	0.6
VCEL Vericel	3.7434 of 5 stars	3.5	5.0	0.0	3.4	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	36.57% Upside
MESO Mesoblast	3.00	Buy	$18.00	62.02% Upside
SRRK Scholar Rock	3.14	Buy	$42.67	13.96% Upside
VCEL Vericel	3.00	Buy	$61.14	53.13% Upside

Current Analyst Ratings Breakdown

Latest SRRK, VCEL, MESO, DBVT, and APTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
6/16/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00
6/3/2025	SRRK Scholar Rock	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
DBVT DBV Technologies	$4.15M	71.28	N/A	N/A	$1.42 per share	7.61
MESO Mesoblast	$5.90M	240.62	N/A	N/A	$4.21 per share	2.64
SRRK Scholar Rock	$33.19M	107.11	N/A	N/A	$3.94 per share	9.50
VCEL Vericel	$237.22M	8.47	$0.30 per share	131.94	$5.92 per share	6.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.53	N/A	N/A	N/A	N/A	-118.22%	-82.01%	8/6/2025 (Estimated)
VCEL Vericel	$10.36M	$0.03	1,331.44	90.75	N/A	1.25%	1.09%	0.73%	7/30/2025 (Estimated)

Latest SRRK, VCEL, MESO, DBVT, and APTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	VCEL Vericel	-$0.04	N/A	N/A	N/A	$64.61 million	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
DBVT DBV Technologies	N/A	0.72	0.72
MESO Mesoblast	0.22	0.96	0.63
SRRK Scholar Rock	0.16	10.25	10.25
VCEL Vericel	N/A	5.01	4.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
DBVT DBV Technologies	71.74%
MESO Mesoblast	1.43%
SRRK Scholar Rock	91.08%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
DBVT DBV Technologies	1.44%
MESO Mesoblast	18.80%
SRRK Scholar Rock	13.30%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
SRRK Scholar Rock	140	94.95 million	82.32 million	Optionable
VCEL Vericel	300	50.34 million	47.73 million	Optionable

SRRK, VCEL, MESO, DBVT, and APTO Headlines

Recent News About These Companies

Vericel Corporation (NASDAQ:VCEL) Receives $61.14 Average Price Target from Analysts

July 5, 2025 | americanbankingnews.com

Allspring Global Investments Holdings LLC Sells 11,632 Shares of Vericel Corporation (NASDAQ:VCEL)

July 4, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from Brokerages

July 2, 2025 | marketbeat.com

Lisanti Capital Growth LLC Acquires 13,585 Shares of Vericel Corporation (NASDAQ:VCEL)

June 29, 2025 | marketbeat.com

If EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An Opportunity

June 20, 2025 | finance.yahoo.com

Conestoga Capital Advisors LLC Sells 7,830 Shares of Vericel Co. (NASDAQ:VCEL)

June 17, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Shares Down 3.8% - What's Next?

June 16, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Receives "Overweight" Rating from Stephens

June 16, 2025 | marketbeat.com

Vericel Corporation: Moving From Sell To Neutral

June 12, 2025 | seekingalpha.com

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

June 11, 2025 | morningstar.comM

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

June 10, 2025 | globenewswire.com

5VCEL : What Analysts Are Saying About Vericel Stock

May 23, 2025 | benzinga.com

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare

May 16, 2025 | investing.com

Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?

May 10, 2025 | aaii.comA

Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

May 9, 2025 | finanznachrichten.de

Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...

May 9, 2025 | finance.yahoo.com

Vericel Corporation 2025 Q1 - Results - Earnings Call Presentation

May 8, 2025 | seekingalpha.com

Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript

May 8, 2025 | seekingalpha.com

Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates

May 8, 2025 | zacks.com

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

May 8, 2025 | globenewswire.com

Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK, VCEL, MESO, DBVT, and APTO Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

DBV Technologies NASDAQ:DBVT

$10.80 -0.03 (-0.28%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$11.00 +0.21 (+1.90%)

As of 07/11/2025 06:05 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Mesoblast NASDAQ:MESO

$11.11 +0.09 (+0.82%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.11 0.00 (0.00%)

As of 07/11/2025 07:57 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Scholar Rock NASDAQ:SRRK

$37.44 -0.68 (-1.78%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$37.47 +0.03 (+0.07%)

As of 07/11/2025 04:20 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Vericel NASDAQ:VCEL

$39.93 -1.30 (-3.15%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$39.92 -0.01 (-0.01%)

As of 07/11/2025 05:06 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time